RxDoctor Payments Data

Emily Unterreiner

Family · Durango, CONPI 1669074985

Payments from drug & device makers

$450in general payments, 2019–2025

Across 11 payments — averaging $40.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stemline Therapeutics Inc.$134
  • Sanofi$109
  • Janssen Scientific Affairs, LLC$56
  • Gilead$46
  • AstraZeneca$30
  • Bristol Myers Squibb$20
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$42093%
  • Education$307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$450 in reported general payments places this provider in the 65th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$55,836
Medicare patients
239
Services billed
725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide59$735,885
RevlimidLenalidomide21$397,239
XtandiEnzalutamide20$270,891
JakafiRuxolitinib Phosphate12$197,058
BrukinsaZanubrutinib16$193,842
NubeqaDarolutamide12$155,063
Abiraterone Acetate24$66,727
EliquisApixaban46$39,157
VarubiRolapitant Hcl14$9,604
Exemestane21$3,425
Oxycodone Hcl71$1,579
Imatinib Mesylate20$1,546
Anastrozole73$1,162
ValacyclovirValacyclovir Hcl18$922
Morphine Sulfate ErMorphine Sulfate37$909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$20$397,23921 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$56$66,72724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,182 family providers in Colorado.

Other family in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →